OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition